Catherine Shaffer

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.

The firm is building a case for clinical utility of its gene expression test for cancer of unknown primary following a successful validation study.

In a Nature Medicine paper, WGS yielded a clinical benefit for 24 percent of pediatric cancer patients, and directly changed clinical management for 7 percent.

Researchers call for more data sharing from single-cell RNA sequencing studies to help validate machine learning precision medicine tools.

The test combining DNA fragmentomics and protein biomarkers had sensitivity ranging from 72 percent to 100 percent for detection of ovarian cancer, depending on disease stage.